BTK and thrombocytopenic purpura: Btk inhibition by PCI-32765 or related molecules is thus a promising direction for therapeutic trials in human IC-mediated diseases such as RA, systemic lupus erythematosus, idiopathic thrombocytopenic purpura, glomerulonephritis, autoimmune-mediated hemolytic anemia, and IC-mediated vasculitis as well as others.